ReviewBioMed research international2017
miRNAs in Prediction of Prognosis in Clear Cell Renal Cell Carcinoma.
Review in BioMed research international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 33 citations in OpenAlex.
- MAGI3 inhibits renal clear cell carcinoma progression through the JAK-STAT3 pathway.Translational andrology and urology · 2026Article
- Network toxicology and single-cell transcriptomics nominate candidate pyrethroid-associated targets and pathways in clear cell renal cell carcinoma.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Emerging roles for the epigenetic modifiers PBRM1 SETD2 and BAP1 in clear cell renal cell carcinoma pathogenesis and prognosis beyond VHL.Discover oncology · 2026Review
- A novel migrasome-associated lncRNA model for clear cell renal cell carcinoma prognosis and immune response prediction.Scientific reports · 2025Article
- hsa-miR-21-5p can serve as a standard biomarker in clear cell renal cell carcinoma by promoting tumor progression and influencing immune evasion.Discover oncology · 2025Article
- Construction of a risk and prognostic model for migrasome-associated lncRNAs in renal cell carcinoma.Scientific reports · 2025Article
- Circular RNA circDVL1 inhibits clear cell renal cell carcinoma progression through the miR-412-3p/PCDH7 axis.International journal of biological sciences · 2022Article
- Silencing of the chemokine CXC receptor 4 (CXCR4) hampers cancer progression and increases cisplatin (DDP)-sensitivity in clear cell renal cell carcinoma (ccRCC).Bioengineered · 2021Article
- Down regulation of miR-30a-5p and miR-182-5p in gastric cancer: Clinical impact and survival analysis.Biochemistry and biophysics reports · 2021Article
- Article
- Let-7i-5p enhances cell proliferation, migration and invasion of ccRCC by targeting HABP4.BMC urology · 2021Article
- Article
- miR-25-3p protects renal tubular epithelial cells from apoptosis induced by renal IRI by targeting DKK3.Open life sciences · 2021Article
- Article
- LINC02738 Participates in the Development of Kidney Cancer Through the miR-20b/Sox4 Axis.OncoTargets and therapy · 2020Article
- Integrin α7 is overexpressed and correlates with higher pathological grade, increased T stage, advanced TNM stage as well as worse survival in clear cell renal cell carcinoma patients: A retrospective study.Journal of clinical laboratory analysis · 2020Article
- miR-22 Regulates Invasion, Gene Expression and Predicts Overall Survival in Patients with Clear Cell Renal Cell Carcinoma.Kidney cancer (Clifton, Va.) · 2019Article
- The miR-183/182/96 cluster functions as a potential carcinogenic factor and prognostic factor in kidney renal clear cell carcinoma.Experimental and therapeutic medicine · 2019Article
- MicroRNA-218 inhibits the cell proliferation and migration in clear cell renal cell carcinoma through targeting cancerous inhibitor of protein phosphatase 2A.Oncology letters · 2019Article
- miR-4521-FAM129A axial regulation on ccRCC progression through TIMP-1/MMP2/MMP9 and MDM2/p53/Bcl2/Bax pathways.Cell death discovery · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal cell carcinoma (RCC) is the most common type of urinary malignancy. Clear cell renal cell carcinoma (ccRCC) is the predominant RCC subtype, accounting for 70-80% of RCC. In recent years, miRNAs have been found to be closely associated with the outcome of the patients with ccRCC. In this review, we summarize recent advances in research exploring the role of miRNAs in predicting prognosis in patients with ccRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.